Goldman Sachs raises its price target for Zeta Global (ZETA), citing strategic positioning ahead of an expected surge in software sector mergers and acquisitions driven by valuation gaps and synergy potential.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.
Analyst firm Piper Sandler reiterates its Overweight rating on AGNC Investment Corp., highlighting a favorable shift in agency mortgage-backed securities spreads that could bolster the REIT's book value.
UBS initiates coverage on Rithm Capital with a Buy rating and a $16 price target, highlighting the REIT's aggressive acquisition strategy—including the purchases of Paramount Group and Crestline—as a key driver for expanding its asset management footprint and unlocking shareholder value.
SharpLink Gaming (NASDAQ: SBET) is drawing bullish attention from major Wall Street firms, with multiple analysts reiterating Buy ratings. The company's substantial Ethereum holdings and management's crypto expertise are seen as key drivers, even as price targets adjust to market conditions.
Innodata Inc. (NASDAQ: INOD), a data engineering and AI services firm, has been awarded a place on a critical U.S. Missile Defense Agency contract vehicle, positioning it for future task orders in defense technology development and fueling analyst optimism for its 2026 growth trajectory.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Truist Securities has slightly lowered its price target on Tesla shares to $438, citing the significant capital expenditure required for the automaker's aggressive shift towards AI and robotics, despite a solid Q4 performance.
Investment firm TD Cowen has increased its price target on Tesla (TSLA) to $519, maintaining a Buy rating. The adjustment follows a fourth-quarter performance marked by strong margins and progress on autonomous driving projects, though tempered by higher capital expenditure forecasts and vague timelines for full self-driving technology.
Truist Securities has lowered its price target on Landstar System (LSTR) from $150 to $145, maintaining a Hold rating following the logistics provider's fourth-quarter earnings miss. Analysts cite one-time insurance costs as a drag, while noting core fundamentals have yet to show a decisive turnaround.
Truist Securities raises its price target on Meta Platforms to $900, maintaining a Buy rating. The upgrade follows stronger-than-expected Q4 results and a robust Q1 outlook, driven by AI enhancements boosting ad performance and user engagement.
Analysts at TD Cowen have increased their price target on logistics giant C.H. Robinson to $194, citing better-than-expected fourth-quarter results and margin resilience in a tough spot market, while maintaining a Hold rating.
Analysts at TD Cowen have significantly raised their price target for GE Vernova (GEV) to $780, maintaining a Buy rating after the company's robust Q4 performance exceeded expectations on orders and pricing power.
Semiconductor security firm SEALSQ deepens its investment in France, now employing around 200 specialists across its Toulouse, Aix-en-Provence, and Grenoble offices, positioning the country as a core R&D center for its post-quantum cryptography and secure chip technologies.
Analysts at Truist Securities have adjusted their outlook for Packaging Corporation of America (PKG), lowering the price target to $270 following a fourth-quarter earnings miss. Despite the revision, the firm reiterates its Buy rating, suggesting the recent stock dip may present a strategic buying opportunity ahead of anticipated strength in the packaging sector.
